Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takeda
Biotech
Hemab CEO seeks ‘flavor of a multi-product coagulation company’
With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
Will Maddox
Aug 13, 2026 9:00am
Zealand sells rights to Takeda’s blood cancer drug for $100M
Aug 13, 2026 5:05am
Silence brings the noise to Takeda with phase 2 blood cancer win
Aug 10, 2026 7:31am
Takeda scraps another phase 2 celiac disease therapy
Jul 30, 2026 9:18am
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
Jul 27, 2026 10:08am
Takeda’s zasocitinib ‘top-notch’ for hard-to-treat psoriasis
Jul 16, 2026 6:00pm
